Bill Baruch Likes AbbVie’s Breakout as Humira Losses Get Replaced
Bill Baruch is looking at AbbVie as a healthcare name outside of the tech trade. He pointed to 7 percent earnings growth and an expected 24 percent revenue growth ahead, with Skyrizi and Rinvoq now making up for the revenue AbbVie lost as Humira came off patent. The stock is only up about 7 percent […]
Bill Baruch’s Final Trade: Nebius Group Set to Snap Back
Bill Baruch joined CNBC’s Halftime Report for his final trade, picking Nebius Group. He calls it an AI infrastructure name with an ultra growth story that has sold off nearly half from its recent high into major support. He thinks that it snaps back quickly, though he flagged it as one of the more volatile […]
Micron’s Pop Signals Capitulation on CapEx Fears, Says Bill Baruch
Bill Baruch flagged Micron as a signal he’s been watching for a couple of weeks. After its last earnings report, memory stocks including Micron ran the following day, and he reads that move as capitulation on the market’s fear around AI CapEx spending. It’s part of a broader thesis he holds on the Mag Seven […]